Viacyte, a Leading Company in the Emerging Field of Cell Replacement Therapy
Mark Zimmerman, Vice President, Strategy and Business Development, Viacyte
The start-up Viacyte was founded to pursue cell therapies for diabetes, with two distinct products designed for type I and type II disease. Both platforms are based on a proprietary cell source and differentiation protocol which allows the production of arbitrarily large numbers of pancreatic progenitor cells capable of maturing in vivo to functional islets. Viacyte’s vice president Mark Zimmerman discussed the company’s progress in clinical translation, including their highly promising phase I results.